Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.75 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.71 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.66 |
| ▸ | NPC1 | O15118 | 1/20 | 0.64 |
| ▸ | RAB9A | P51151 | 1/20 | 0.64 |
| ▸ | LMNA | P02545 | 3/20 | 0.62 |
| ▸ | RGS12 | O14924 | 1/20 | 0.62 |
| ▸ | MAPT | P10636 | 1/20 | 0.62 |
| ▸ | USP2 | O75604 | 1/20 | 0.62 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.62 |
| ▸ | CASP1 | P29466 | 1/20 | 0.62 |
| ▸ | CASP7 | P55210 | 1/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.62 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.62 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.62 |
| ▸ | ATM | Q13315 | 1/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.60 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10675941 | 0.83 | ALDH1A1 (0.54) | ALDH1A1KMT2ACYP2C19NPC1RAB9A | |
| SCHEMBL10681856 | 0.81 | ALDH1A1 (0.54) | ALDH1A1KMT2ACYP2C19NPC1RAB9A | |
| SCHEMBL10403688 | 0.76 | ALDH1A1 (0.60) | ALDH1A1KMT2ANPC1RAB9ALMNA | |
| SCHEMBL5533990 | 0.76 | ALDH1A1 (0.60) | ALDH1A1KMT2ANPC1RAB9ALMNA | |
| SCHEMBL25334790 | 0.75 | ALDH1A1 (0.67) | ALDH1A1KMT2ANPC1RAB9AMAPT | |
| SCHEMBL11166347 | 0.74 | ALDH1A1 (0.58) | ALDH1A1KMT2ANPC1RAB9ALMNA | |
| SCHEMBL9547388 | 0.74 | ALDH1A1 (0.58) | ALDH1A1KMT2ANPC1RAB9ALMNA | |
| SCHEMBL11518064 | 0.74 | ALDH1A1 (0.58) | ALDH1A1KMT2ANPC1RAB9ALMNA | |
| SCHEMBL22016331 | 0.73 | ALDH1A1 (0.70) | ALDH1A1KMT2ARAB9ALMNASMN1; SMN2 | |
| SCHEMBL10457059 | 0.73 | ALDH1A1 (0.56) | ALDH1A1KMT2ANPC1RAB9ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12564547-B2 | Compositions, formulations, and methods for skin treatment | ODDITY LABS, LLC (US) | 2026-03-03 | — | — | US | disclosed |
| US-20230240960-A1 | COMPOSITIONS, FORMULATIONS, AND METHODS FOR SKIN TREATMENT | ODDITY LABS, LLC | 2023-08-03 | — | — | US | disclosed |
| US-20230240960-A1 | COMPOSITIONS, FORMULATIONS, AND METHODS FOR SKIN TREATMENT | ODDITY LABS, LLC | 2023-08-03 | — | — | US | disclosed |
| US-20230240960-A1 | COMPOSITIONS, FORMULATIONS, AND METHODS FOR SKIN TREATMENT | ODDITY LABS, LLC | 2023-08-03 | — | — | US | disclosed |
| WO-2023133240-A1 | COMPOSITIONS, FORMULATIONS, AND METHODS FOR SKIN TREATMENT | REVELA, INC. (US) | 2023-07-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230240960-A1 | COMPOSITIONS, FORMULATIONS, AND METHODS FOR SKIN TREATMENT | CUTA, COL14A1, DSG1 | ALDH1A1 3302/4885KMT2A 2123/4885CYP2C19 2145/4885 |
| US-12564547-B2 | Compositions, formulations, and methods for skin treatment | MCOLN1, H1-0, APOL1 | ALDH1A1 1590/4885KMT2A 2155/4885CYP2C19 2704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.